In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
no speaker photo
Speaker
Bertram Pitt
Bertram Pitt Bertram Pitt

University of Michigan, Ann Arbor (United States of America)

Specialities : Acute Heart Failure , Acute Heart Failure, Hypertension

28 presentations from this speaker

Changing the treatment paradigm of hyperkalaemia management to enable and optimize renin-angiotensin-aldosterone system inhibitors therapy.

Event : Heart Failure 2018

  • Session : Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors?
  • Speaker : B Pitt (Ann Arbor,US)
  • Sponsored by Vifor Pharma

Conclusions - Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors therapy.

Event : Heart Failure 2018

  • Session : Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors therapy
  • Speaker : B Pitt (Ann Arbor,US)
  • Sponsored by Vifor Pharma

Introduction - Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors therapy.

Event : Heart Failure 2018

  • Session : Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors therapy
  • Speaker : B Pitt (Ann Arbor,US)
  • Sponsored by Vifor Pharma

Potassium binders

Event : Heart Failure 2018

  • Session : Novel drugs in heart failure
  • Speaker : B Pitt (Ann Arbor,US)

Potassium binding - Available evidence and ongoing trials in chronic heart failure

Event : Heart Failure 2018

  • Session : Potassium - Friend or foe?
  • Speaker : B Pitt (Ann Arbor,US)

Diuretic management: new opportunities.

Event : Heart Failure 2017

  • Session : Cardiorenal cross-roads
  • Speaker : B Pitt (Ann Arbor,US)

Enabling and optimizing RAASi therapy in cardio-renal patients by controlling potassium level.

Event : Heart Failure 2017

  • Session : Enabling and optimizing Renin-Angiotensin-Aldosterone-System inhibitors (RAASi) therapy in cardio-renal patients by controlling potassium levels
  • Speaker : B Pitt (Ann Arbor,US)
  • Sponsored by Vifor Pharma/Vifor Fresenius Medical Care Renal Pharma

Panel discussion.

Event : Heart Failure 2017

  • Session : Enabling and optimizing Renin-Angiotensin-Aldosterone-System inhibitors (RAASi) therapy in cardio-renal patients by controlling potassium levels
  • Speaker : B Pitt (Ann Arbor,US)
  • Sponsored by Vifor Pharma / Vifor Fresenius Medical Care Renal Pharma

Potassium binders.

Event : Heart Failure 2017

  • Session : Novel drugs: how do they work?
  • Speaker : B Pitt (Ann Arbor,US)

Targeting multi-organ dysfunction in heart failure: a mitochondrial approach.

Event : Heart Failure 2017

  • Session : A mitochondrial approach to heart failure
  • Speaker : B Pitt (Ann Arbor,US)
  • Sponsored by Charité Universitätsmedizin Berlin

Welcome and introduction.

Event : Heart Failure 2017

  • Session : Enabling and optimizing Renin-Angiotensin-Aldosterone-System inhibitors (RAASi) therapy in cardio-renal patients by controlling potassium levels
  • Speaker : B Pitt (Ann Arbor,US)
  • Sponsored by Vifor Pharma / Vifor Fresenius Medical Care Renal Pharma

Clinical development concepts targeting mitochondria.

Event : Heart Failure 2016

  • Session : Targeting mitochondria to improve outcomes in heart failure
  • Speaker : B Pitt (Ann Arbor,US)
  • Organised by Charité Medical School Berlin, supported by an unrestricted educational grant from Stealth Peptides

Furosemide 2.0: a novel formulation of furosemide for subcutaneous administration.

Event : Heart Failure 2016

  • Session : Furosemide 2.0: furosemide for subcutaneous administration: a novel tool in the management of the pre and post acute heart failure patient
  • Speaker : B Pitt (Ann Arbor,US)
  • Sponsored by scPharmaceuticals

Potassium binders studied in CKD.

Event : Heart Failure 2016

  • Session : What heart failure specialists can learn from trials in other disease areas
  • Speaker : B Pitt (Ann Arbor,US)

Potassium lowering drugs.

Event : Heart Failure 2016

  • Session : Novel heart failure therapies
  • Speaker : B Pitt (Ann Arbor,US)

Summary and close.

Event : Heart Failure 2016

  • Session : Hyperkalaemia: are your patients missing out?
  • Speaker : B Pitt (Ann Arbor,US)
  • Sponsored by Vifor Pharma

Welcome and introduction.

Event : Heart Failure 2016

  • Session : Hyperkalaemia: are your patients missing out?
  • Speaker : CS Lam (Singapore,SG), B Pitt (Ann Arbor,US)
  • Sponsored by Vifor Pharma

A case of HFpEF with EF 45% and its treatment.

Event : ESC Congress 2015

  • Session : Heart failure
  • Speaker : B Pitt (Ann Arbor,US)

Discussion: HARMONIZE.

Event : Heart Failure 2015

  • Session : Late Breaking Trials I: Therapies for acute and advanced heart failure
  • Speaker : B Pitt (Ann Arbor,US)

Effect of cardiovascular comorbidities on the mortality risk associated with serum potassium

Event : Heart Failure 2015

  • Session : Population studies / Epidemiology
  • Speaker : B Pitt (Ann Arbor,US)

Mineralcorticoid receptor antagonism.

Event : Heart Failure 2015

  • Session : The success of neurohormonal blockade: looking back – looking forward
  • Speaker : B Pitt (Ann Arbor,US)

Novel mineralocorticoid receptor antagonists.

Event : Heart Failure 2015

  • Session : Acute heart failure: novel therapies on the horizon
  • Speaker : B Pitt (Ann Arbor,US)

Benefit / risk of potassium and aldosterone antagonism.

Event : ESC Congress 2014

  • Session : Sudden death and pharmacotherapy
  • Speaker : B Pitt (Ann Arbor,US)

New aldosterone antagonists.

Event : ESC Congress 2014

  • Session : Emerging therapies in acute heart failure
  • Speaker : B Pitt (Ann Arbor,US)

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are